1. Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
   Wenxiong Zhang et al, 2018, BMC Cancer CrossRef
2. Surgical outcomes in lung cancer presenting as ground-glass opacities of 3 cm or less: A review of 5 years' experience
   Chi-Wei Duann et al, 2013, Journal of the Chinese Medical Association CrossRef
3. Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer
   Wenxiong Zhang et al, 2018, Medicine CrossRef
4. Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
   Sohita Dhillon, 2015, Targeted Oncology CrossRef
5. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
   Kazuhiro Asami, 2014, World Journal of Clinical Oncology CrossRef
6. Sialidase Attenuates Epidermal Growth Factor Response and Abolishes Antiproliferative Effects of Erlotinib in A549Alveolar Epithelial Cells
   A. Rybak et al, 2019, Medical Science and Research CrossRef
7. Mutated Ephrin Receptor Genes in Non‐Small Cell Lung Carcinoma and Their Occurrence with Driver Mutations—Targeted Resequencing Study on Formalin‐Fixed, Paraffin‐Embedded Tumor Material of 81 Patients
   Satu Mäki‐Nevala et al, 2013, Genes, Chromosomes and Cancer CrossRef
8. Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
   Wen-Shuo Wu et al, 2014, Journal of Personalized Medicine CrossRef
9. Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis
   Zuyao Yang et al, 2017, International Journal of Cancer CrossRef
10. Predictive Tumor Biomarkers for EGFR Inhibitors
    Lucia Kim et al, 2014, Lung Cancer CrossRef
11. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer
    Wen-Shuo Wu et al, 2013, Journal of the Chinese Medical Association CrossRef
12. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
    Giuseppe Bronte et al, 2014, Critical Reviews in Oncology/Hematology CrossRef
13. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non‑small cell lung cancer: A network meta‑analysis
    Yuanyuan Liu et al, 2017, Experimental and Therapeutic Medicine CrossRef
14. Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment
    Wen-Shuo Wu et al, 2016, American Journal of Clinical Oncology CrossRef
15. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
    Yuh-Min Chen, 2013, Journal of the Chinese Medical Association CrossRef